This Research Topic is one volume within the series "The Future of Checkpoint Immunotherapy: New Roads Ahead". Please see the ...

The clinical results from several trials suggest that patients get a high response rate from enfortumab vedotin (the antibody-drug conjugate) that is made durable from pembrolizumab (the checkpoint ...

The timing of myocarditis onset during immunotherapy treatment for cancer may predict how likely a person is to die of the condition, according to retrospective study results.Patients who developed my ...

Cancer immunotherapy has historically focused on harnessing the ability of T cells to recognize and attack cancer cells. Adaptive immune checkpoint inhibitors (ICIs) unleash tumor-infiltrating ...

New research has uncovered immune changes in cancer patients that could help identify which patients are most at risk of dangerous heart complications from cancer drugs, known as immune checkpoint ...

A retrospective study highlights the potential for encephalitis and other serious neurologic side effects over the course of ...

ANKTIVA, in combination with an immune checkpoint inhibitor, has received accelerated approval from the Saudi Food and Drug Authority for the treatment of metastatic non-small cell lung cancer, ...

Please provide your email address to receive an email when new articles are posted on . Glucocorticoids remain the primary option for immune-related adverse events of checkpoint inhibitor therapy in ...

ICIs are safe and effective for HIV-positive NSCLC patients, with no significant differences in survival outcomes compared to HIV-negative patients. Studies included in the review were mostly ...